Academic Journal

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility

التفاصيل البيبلوغرافية
العنوان: In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility
المؤلفون: J. Christian Virchow, Lisa Hickey, Evelyn Du, Margaret Garin
المصدر: Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-8 (2020)
بيانات النشر: BMC, 2020.
سنة النشر: 2020
المجموعة: LCC:Immunologic diseases. Allergy
مصطلحات موضوعية: Asthma, Clinical trials, Eosinophils, Lung function, Immunologic diseases. Allergy, RC581-607
الوصف: Abstract Background A post hoc analysis of two randomized, placebo–controlled, Phase 3 trials of intravenous reslizumab, an anti-interleukin-5 (IL-5) biologic for severe eosinophilic asthma. Methods Relationships between baseline blood eosinophil levels (EOS), forced expiratory volume in 1 s (FEV1) reversibility to β2-agonists and treatment outcomes were assessed. Results Mean baseline FEV1 reversibility was numerically lower among patients with high (≥ 400 cells/µL) versus low baseline EOS. Reslizumab produced clinically significant improvement in FEV1, exacerbation rates and patient-reported outcomes after 52 weeks, including in patients with high EOS and low FEV1 reversibility (≤ 14%) to β2-agonists at baseline. Conclusions Clinical trial eligibility criteria stipulating minimum FEV1 reversibility to β2-agonists of ≥ 12% might exclude patients who would benefit from treatment with anti-IL-5 biologics.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1710-1492
Relation: http://link.springer.com/article/10.1186/s13223-020-00424-2; https://doaj.org/toc/1710-1492
DOI: 10.1186/s13223-020-00424-2
URL الوصول: https://doaj.org/article/50d1273204b643ed93e6c67328950ea6
رقم الانضمام: edsdoj.50d1273204b643ed93e6c67328950ea6
قاعدة البيانات: Directory of Open Access Journals